Status:

COMPLETED

Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat

Lead Sponsor:

Akebia Therapeutics

Conditions:

Drug Interaction Potentiation

Pharmacokinetics

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

This is a Phase 1, fixed sequence, open-label study to evaluate the effect of multiple oral doses of rabeprazole on the pharmacokinetics of a single dose of vadadustat 300 mg in healthy male and femal...

Detailed Description

This is a Phase 1, fixed sequence, open-label study in healthy adult subjects to evaluate the effect of multiple doses of rabeprazole on the pharmacokinetics of a single dose of vadadustat in healthy ...

Eligibility Criteria

Inclusion

  • Healthy Male or female between 18 and 55 years of age, inclusive, at time of informed consent
  • Body mass index between 18.0 and 30.0 kg/m2, with a minimum body weight of 45 kg for females and 50 kg for males, inclusive.

Exclusion

  • Current or past clinically significant history of cardiovascular, cerebrovascular, pulmonary, gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, or other major disease. History of cancer (except treated non-melanoma skin cancer) or history of chemotherapy use within 5 years prior to Screening.
  • Positive test results for human immunodeficiency virus (HIV) antibody; Positive test results of hepatitis B surface antigen (HBsAg), or positive hepatitis C virus antibody (HCVab) within 3 months prior to screening , or positive test results for human immunodeficiency virus antibody (HIVab) at Screening
  • Taking any prescription medication or over the counter multi-vitamin supplement, or any non-prescription products (including herbal-containing preparations but excluding acetaminophen) within 14 days prior to Day -1.

Key Trial Info

Start Date :

October 3 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 19 2018

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT03789032

Start Date

October 3 2018

End Date

November 19 2018

Last Update

March 22 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

inVentiv Health Clinique Inc.

Québec, Quebec, Canada, G1P 0A2